This is a StreetInsider.com Premium Only Page

(INKT) –

Apr 8, 2024 12:01 PM MiNK Therapeutics (INKT) Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Apr 8, 2024 12:00 PM MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024 04:06 PM Form 10-K MiNK Therapeutics, Inc. For: Dec 31

Mar 21, 2024 07:35 AM MiNK Therapeutics, Inc. (INKT) Misses Q4 EPS by 1c

Mar 21, 2024 07:00 AM Form 8-K MiNK Therapeutics, Inc. For: Mar 21

Mar 21, 2024 07:00 AM MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024 07:30 AM MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 7, 2024 07:30 AM MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024 08:30 AM MiNK Therapeutics (INKT) Announces Preclinical Data Showcasing Activity of MiNK-215

Mar 6, 2024 08:30 AM MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

Mar 5, 2024 06:01 PM Form 4 MiNK Therapeutics, Inc. For: Mar 01 Filed by: Behner Peter

Mar 5, 2024 06:00 PM Form 4 MiNK Therapeutics, Inc. For: Mar 01 Filed by: Ryan Barbara

Mar 5, 2024 06:00 PM Form 4 MiNK Therapeutics, Inc. For: Mar 01 Filed by: WIINBERG ULF

Mar 5, 2024 06:00 PM Form 4 MiNK Therapeutics, Inc. For: Mar 01 Filed by: Corvese Brian

Feb 29, 2024 04:06 PM Form 8-K MiNK Therapeutics, Inc. For: Feb 23

Feb 14, 2024 06:06 PM Form SC 13D MiNK Therapeutics, Inc. Filed by: ARMEN GARO H

Feb 14, 2024 08:01 AM Form 8-K MiNK Therapeutics, Inc. For: Feb 12

Feb 14, 2024 08:00 AM First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Feb 6, 2024 08:02 AM MiNK Therapeutics' (INKT) AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress

Feb 6, 2024 08:00 AM MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Feb 6, 2024 08:00 AM MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

Jan 30, 2024 08:00 AM MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Jan 18, 2024 08:00 PM Form 4 MiNK Therapeutics, Inc. For: Jan 18 Filed by: Buell Jennifer

Jan 18, 2024 08:00 PM Form 4 MiNK Therapeutics, Inc. For: Jan 16 Filed by: van Dijk Marcus Antonius

Dec 20, 2023 07:31 AM MiNK Therapeutics (INKT) and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Dec 20, 2023 07:30 AM ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Dec 5, 2023 06:11 PM Form 4 MiNK Therapeutics, Inc. For: Dec 01 Filed by: Ryan Barbara

Dec 5, 2023 06:06 PM Form 4 MiNK Therapeutics, Inc. For: Dec 01 Filed by: Corvese Brian

Dec 5, 2023 06:05 PM Form 4 MiNK Therapeutics, Inc. For: Dec 01 Filed by: WIINBERG ULF

Dec 5, 2023 06:05 PM Form 4 MiNK Therapeutics, Inc. For: Dec 01 Filed by: Behner Peter

Nov 14, 2023 07:30 PM Form 10-Q MiNK Therapeutics, Inc. For: Sep 30

Nov 9, 2023 07:00 AM MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 9, 2023 07:00 AM Form 8-K MiNK Therapeutics, Inc. For: Nov 09

Nov 3, 2023 12:02 PM MiNK Therapeutics (INKT) Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors

Nov 3, 2023 12:00 PM MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023 08:00 AM MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Oct 17, 2023 04:18 PM MiNK Therapeutics (INKT) Announces Resignation of John Baldoni from Board

Oct 17, 2023 04:15 PM Form 8-K MiNK Therapeutics, Inc. For: Oct 12

Oct 16, 2023 05:50 PM Form 4 MiNK Therapeutics, Inc. For: Oct 12 Filed by: AGENUS INC

Oct 13, 2023 08:19 PM Form 4 MiNK Therapeutics, Inc. For: Oct 11 Filed by: Buell Jennifer

Oct 6, 2023 04:27 PM Form 4 MiNK Therapeutics, Inc. For: Oct 04 Filed by: AGENUS INC

Oct 3, 2023 09:15 PM Form 4 MiNK Therapeutics, Inc. For: Sep 29 Filed by: Buell Jennifer

Sep 29, 2023 04:43 PM Form 4 MiNK Therapeutics, Inc. For: Sep 27 Filed by: Buell Jennifer

Sep 27, 2023 09:05 AM MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Sep 6, 2023 05:04 PM Form 4 MiNK Therapeutics, Inc. For: Sep 01 Filed by: Behner Peter

Sep 6, 2023 05:03 PM Form 4 MiNK Therapeutics, Inc. For: Sep 01 Filed by: Corvese Brian

Sep 6, 2023 05:02 PM Form 4 MiNK Therapeutics, Inc. For: Sep 01 Filed by: Baldoni John

Sep 6, 2023 05:01 PM Form 4 MiNK Therapeutics, Inc. For: Sep 01 Filed by: Ryan Barbara

Sep 6, 2023 05:01 PM Form 4 MiNK Therapeutics, Inc. For: Sep 01 Filed by: WIINBERG ULF

Aug 31, 2023 05:54 PM Form 4 MiNK Therapeutics, Inc. For: Aug 29 Filed by: AGENUS INC